Notes
including cinoxacin, ciprofloxacin, flumequine, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, pefloxacin, pipemidic acid, prulifloxacin and rufloxacin.
CHMP = Committee for Medicinal Products for Human Use
Reference
European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Internet Document : [3 pages], 16 Nov 2018. Available from: URL: https://www.ema.europa.eu/en/news/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone
Rights and permissions
About this article
Cite this article
EU restrictions for quinolone antibacterials due to serious ADRs. Reactions Weekly 1730, 1 (2018). https://doi.org/10.1007/s40278-018-54901-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-54901-8